Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-25T05:57:55.011Z Has data issue: false hasContentIssue false
  • English
  • Français

The Urgent Need for Monitoring and Intervention to Reduce Metabolic Risk Factors in Patients with Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Henry A. Nasrallah
Get access Rights & Permissions [Opens in a new window]

Extract

Serious mental illness is associated with a significant reduction in life expectancy of ≤30 years. Among patients with schizophrenia, mortality due to coronary heart disease is ∼50% higher than that of the general population.

Patients with schizophrenia have substantially higher rates of cardiovascular risk factors (smoking, high cholesterol, hypertension, physical inactivity, obesity/overweight, and diabetes) than the general population. Approximately 75% of individuals with schizophrenia smoke compared to ∼25% of the general population. Patients with schizophrenia also have lipid profiles that are significantly worse than those of individuals in the general population.

Type
Clinical Information Supplement
Information
CNS Spectrums , Volume 13 , supplement S10: Elevating the Standard of Care in the Management of Cardiometabolic Risk Factors in Patients with Mental Illness , June 2008 , pp. 5 - 6
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Meloni, D, Miccinesi, G, Bencini, A, et al. Mortality among discharged psychiatric patients in Florence, Italy. Psychiatr Serv. 2006;57(10):1474–1481.Google Scholar
2. Miller, BJ, Paschall, CB III, Svendsen, DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv. 2006;57(10):1482–1487.Google Scholar
3. Hennekens, CH, Hennekens, AR, Hollar, D, Casey, DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–1121.Google Scholar
4. Cohn, T, Prud'homme, D, Streiner, D, Kameh, H, Remington, G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753–760.Google Scholar
5. Lambert, TJ, Velakoulis, D, Pantelis, C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178 (suppl):S67–S70.Google Scholar
6. National Diabetes Fact Sheet: United States, 2005. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/diabetes/pubs/factsheet05.htm. Accessed Accessed May 22, 2008.Google Scholar
7. Davidson, M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002;63(suppl 9):5–11.Google Scholar
8. Goff, DC, Sullivan, LM, McEvoy, JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53.Google Scholar
9. Newcomer, JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67 (suppl 9):25–30.Google Scholar
10. Regenold, WT, Thapar, RK, Marano, C, Gavirneni, S, Kondapavuluru, PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002;70(1):19–26.Google Scholar
11. McEvoy, JP, Meyer, JM, Goff, DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.CrossRefGoogle ScholarPubMed
12. Grundy, SM, Cleeman, JI, Merz, CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.Google Scholar
13. Nasrallah, HA, Meyer, JM, Goff, DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1–3):15–22.Google Scholar
14. Lieberman, JA, Stroup, TS, McEvoy, JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.Google Scholar
15. Newcomer, JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004;26(12):1936–1946.Google Scholar